000303420 001__ 303420
000303420 005__ 20250810022013.0
000303420 0247_ $$2doi$$a10.1186/s12885-025-14489-y
000303420 0247_ $$2pmid$$apmid:40775303
000303420 0247_ $$2altmetric$$aaltmetric:180091265
000303420 037__ $$aDKFZ-2025-01645
000303420 041__ $$aEnglish
000303420 082__ $$a610
000303420 1001_ $$aNeu, Marie Astrid$$b0
000303420 245__ $$aGet strong to fight childhood cancer - an exercise intervention for children and adolescents undergoing anti-cancer treatment (FORTEe): Rationale and design of a randomized controlled exercise trial.
000303420 260__ $$aLondon$$bBioMed Central$$c2025
000303420 3367_ $$2DRIVER$$aarticle
000303420 3367_ $$2DataCite$$aOutput Types/Journal article
000303420 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754661127_12329
000303420 3367_ $$2BibTeX$$aARTICLE
000303420 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303420 3367_ $$00$$2EndNote$$aJournal Article
000303420 500__ $$aWiskemann D120 ?
000303420 520__ $$aDespite substantial advances in treatment, children and adolescents with cancer continue to face high morbidity and health issues, including cancer-related fatigue, treatment-related complications, and physical inactivity. Integrating exercise into pediatric oncology care has emerged as a promising approach to mitigate these burdens during cancer treatment. While preliminary data support its potential to reduce treatment-related side effects and enhance quality of life, robust evidence -especially from large, multicenter trials- remains limited.The FORTEe trial is a randomized, controlled, multicenter trial evaluating a personalized and standardized exercise intervention powered to include 450 children, adolescents, and young adults undergoing cancer treatment across ten centers in Europe. The trial aims to provide high-quality evidence for integrating precision exercise therapy as part of standard care. Participants are randomly assigned to either the exercise intervention group, receiving a tailored, supervised 8-10 weeks lasting exercise program, or the control group, receiving usual care. The exercise program includes endurance, strength, flexibility, and balance training, adapted to each patient's age, fitness, and cancer treatment phase. Exercise sessions are intended to take place 3-5 times a week with moderate intensity, with both frequency and intensity adapted to the clinical condition of the individual. Digital tools and telehealth solutions support the intervention, allowing for both in-person and remote training.With a target enrolment of 450 patients, the FORTEe trial will be one of the largest interventional studies in pediatric exercise oncology. Given that childhood cancer is a rare disease, this sample size is only achievable through a multicenter approach. Enhancing statistical power, the large sample will enable more robust analyses of the intervention's effects in a diverse population across multiple European centers.As a progress beyond the current state-of-the-art, FORTEe has the ambition to implement pediatric exercise oncology as an evidence-based treatment option for all childhood cancer patients, ultimately integrating it as a standard into clinical practice worldwide.The FORTEe trial was prospectively registered in the German Clinical Trials Register (DRKS00027978) on 28 January 2022 and on ClinicalTrials.gov (NCT05289739) on 21 March 2022.
000303420 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303420 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303420 650_7 $$2Other$$aCancer-related fatigue
000303420 650_7 $$2Other$$aChildhood cancer
000303420 650_7 $$2Other$$aExercise intervention
000303420 650_7 $$2Other$$aPediatric Oncology
000303420 650_7 $$2Other$$aPhysical activity
000303420 650_7 $$2Other$$aRandomized controlled trial
000303420 650_7 $$2Other$$aSupportive Care
000303420 650_7 $$2Other$$aTraining
000303420 650_2 $$2MeSH$$aHumans
000303420 650_2 $$2MeSH$$aAdolescent
000303420 650_2 $$2MeSH$$aChild
000303420 650_2 $$2MeSH$$aNeoplasms: therapy
000303420 650_2 $$2MeSH$$aExercise Therapy: methods
000303420 650_2 $$2MeSH$$aQuality of Life
000303420 650_2 $$2MeSH$$aRandomized Controlled Trials as Topic
000303420 650_2 $$2MeSH$$aMale
000303420 650_2 $$2MeSH$$aFemale
000303420 650_2 $$2MeSH$$aYoung Adult
000303420 650_2 $$2MeSH$$aMulticenter Studies as Topic
000303420 7001_ $$aDreismickenbecker, Elias$$b1
000303420 7001_ $$aLanfranconi, Francesca$$b2
000303420 7001_ $$aStössel, Sandra$$b3
000303420 7001_ $$aBalduzzi, Adriana$$b4
000303420 7001_ $$aWright, Peter$$b5
000303420 7001_ $$aWindsor, Stan$$b6
000303420 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b7$$udkfz
000303420 7001_ $$0P:(DE-He78)04193f5c55d4ad01e93464e1d10950ee$$aEl-Rajab, Inaam$$b8
000303420 7001_ $$aLucia, Alejandro$$b9
000303420 7001_ $$aFiuza-Luces, Carmen$$b10
000303420 7001_ $$aMongondry, Rodolf$$b11
000303420 7001_ $$aFridh, Martin Kaj$$b12
000303420 7001_ $$aSpreafico, Filippo$$b13
000303420 7001_ $$aKonda, Barbara$$b14
000303420 7001_ $$aKitanovski, Lidija$$b15
000303420 7001_ $$aHeißerer, Barbara$$b16
000303420 7001_ $$aPolak, Marco$$b17
000303420 7001_ $$aBaader, Tobias$$b18
000303420 7001_ $$aBloch, Wilhelm$$b19
000303420 7001_ $$aGötte, Miriam$$b20
000303420 7001_ $$aActiveOncoKids, Network$$b21$$eCollaboration Author
000303420 7001_ $$aRizvi, Katie$$b22
000303420 7001_ $$aEurope, Youth Cancer$$b23$$eCollaboration Author
000303420 7001_ $$aRuckes, Christian$$b24
000303420 7001_ $$aPaul, Norbert W$$b25
000303420 7001_ $$aFaber, Joerg$$b26
000303420 7001_ $$aConsortium, FORTEe$$b27$$eCollaboration Author
000303420 7001_ $$aSchwalber, Ameli$$b28$$eContributor
000303420 7001_ $$aPérol, Olivia$$b29$$eContributor
000303420 7001_ $$aLarsen, Hanne Bækgaard$$b30$$eContributor
000303420 7001_ $$aMoriggi, Tommaso Pietro$$b31$$eContributor
000303420 7001_ $$aZardo, William$$b32$$eContributor
000303420 7001_ $$aBertrand, Amandine$$b33$$eContributor
000303420 7001_ $$aWypyrsczyk, Lena$$b34$$eContributor
000303420 7001_ $$aKühn, Mareike$$b35$$eContributor
000303420 7001_ $$aRobinson, Abigale$$b36$$eContributor
000303420 7001_ $$aDiel, Heidi$$b37$$eContributor
000303420 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-025-14489-y$$gVol. 25, no. 1, p. 1275$$n1$$p1275$$tBMC cancer$$v25$$x1471-2407$$y2025
000303420 909CO $$ooai:inrepo02.dkfz.de:303420$$pVDB
000303420 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000303420 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)04193f5c55d4ad01e93464e1d10950ee$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000303420 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303420 9141_ $$y2025
000303420 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:34:06Z
000303420 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:34:06Z
000303420 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-04-10T15:34:06Z
000303420 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-20
000303420 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-20
000303420 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000303420 980__ $$ajournal
000303420 980__ $$aVDB
000303420 980__ $$aI:(DE-He78)D120-20160331
000303420 980__ $$aUNRESTRICTED